• Title/Summary/Keyword: High dose rate brachytherapy

Search Result 93, Processing Time 0.034 seconds

Validation of electromagnetic physics models and electron range in Geant4 Brachytherapy application

  • A. Albqoor ;E. Ababneh ;S. Okoor;I. Zahran
    • Nuclear Engineering and Technology
    • /
    • v.55 no.1
    • /
    • pp.229-237
    • /
    • 2023
  • The mechanics underlying photon and electron interactions was validated using our developed Brachytherapy computer code for high Dose Rate (HDR). By comparing the photon cross-section utilizing multiple physics libraries in the developed code, the results were benchmarked against experimental and theoretical findings. Klein-Nishina and experimental cross-section results were in good agreement with the Livermore library results. For two therapeutically relevant materials, the first scattered electron range was measured within 1 mm and 2 mm, which has significant implications for the interpretation of the kernel dose spikes observed in previous research.

A Case of Radiation Bronchitis Induced Massive Hemoptysis after High-Dose-Rate Endobronchial Brachytherapy

  • Lee, Seok Jeong;Lee, Jong-Young;Jung, Soon Hee;Lee, Shun Nyung;Lee, Ji-Ho;Kim, Chong Whan;Jung, Saehyun;Jung, Ye-Ryung;Lee, Won-Yeon
    • Tuberculosis and Respiratory Diseases
    • /
    • v.73 no.6
    • /
    • pp.325-330
    • /
    • 2012
  • High-dose-rate endobronchial brachytherapy (HDREB) have been used as the treatment of early endobronchial cancer, as well as for palliation of advanced cancer. However, fatal hemoptysis can occur after HDREB at the rate of 7~32%. We report a case of massive hemoptysis due to radiation bronchitis developed after HDREB. A 67-year-old man was treated with HDREB for early endobronchial cancer on the left upper lobe bronchus. He complained of persistent cough from 4 weeks after completion of HDREB. Radiation bronchitis was observed on the bronchoscopy at 34 weeks, and it was progressed from mucosal swelling and exudate formation to necrosis and ulceration without local relapse. In addition, he died of massive hemoptysis after 15 months. The patient had no sign or radiologic evidences to predict the hemoptysis. This case implies that HDREB directly contributes to an occurrence of a fatal hemoptysis, and follow-up bronchoscopy is important to predict a progression of radiation bronchitis and fatal hemoptysis.

Dose Verification Study of Brachytherapy Plans Using Monte Carlo Methods and CT Images (CT 영상 및 몬테칼로 계산에 기반한 근접 방사선치료계획의 선량분포 평가 방법 연구)

  • Cheong, Kwang-Ho;Lee, Me-Yeon;Kang, Sei-Kwon;Bae, Hoon-Sik;Park, So-Ah;Kim, Kyoung-Joo;Hwang, Tae-Jin;Oh, Do-Hoon
    • Progress in Medical Physics
    • /
    • v.21 no.3
    • /
    • pp.253-260
    • /
    • 2010
  • Most brachytherapy treatment planning systems employ a dosimetry formalism based on the AAPM TG-43 report which does not appropriately consider tissue heterogeneity. In this study we aimed to set up a simple Monte Carlo-based intracavitary high-dose-rate brachytherapy (IC-HDRB) plan verification platform, focusing particularly on the robustness of the direct Monte Carlo dose calculation using material and density information derived from CT images. CT images of slab phantoms and a uterine cervical cancer patient were used for brachytherapy plans based on the Plato (Nucletron, Netherlands) brachytherapy planning system. Monte Carlo simulations were implemented using the parameters from the Plato system and compared with the EBT film dosimetry and conventional dose computations. EGSnrc based DOSXYZnrc code was used for Monte Carlo simulations. Each $^{192}Ir$ source of the afterloader was approximately modeled as a parallel-piped shape inside the converted CT data set whose voxel size was $2{\times}2{\times}2\;mm^3$. Bracytherapy dose calculations based on the TG-43 showed good agreement with the Monte Carlo results in a homogeneous media whose density was close to water, but there were significant errors in high-density materials. For a patient case, A and B point dose differences were less than 3%, while the mean dose discrepancy was as much as 5%. Conventional dose computation methods might underdose the targets by not accounting for the effects of high-density materials. The proposed platform was shown to be feasible and to have good dose calculation accuracy. One should be careful when confirming the plan using a conventional brachytherapy dose computation method, and moreover, an independent dose verification system as developed in this study might be helpful.

Intracavitary Ultrasound Hyperthermia Applicators for Gynecological Cancer

  • Lee, Rena J. .;Suh, Hyun-Suk
    • Proceedings of the Korean Society of Medical Physics Conference
    • /
    • 2003.09a
    • /
    • pp.53-53
    • /
    • 2003
  • For evaluating the feasibility of treating recurrent lesions in the vaginal cuff and cervix by hyperthermia, ultrasound applicators were designed, constructed, and characterized. For the treatment A half-cylindrical transducer Cd=1cm, length=lcm) and cylindrical transducer (d=2.5cm, length= 1.5cm) were used to construct ovoid type and cylindrical applicators. For the ovoid type applicator, each element was operated at 1.5MHz and characterized by measuring transducer efficiency and acoustic power distribution. Thermocouple probes were used to measure the temperature rise in phantom. The element sizes used in this study were selected to be comparable for high dose rate brachytherapy colpostat applicator. Each element was powered separately to achieve a desired temperature pattern in a target. The acoustic output power as a function of applied electric power of the element 1 and 2 was linear over this 1 to 40 W range and efficiencies were 32.2${\pm}$3.4% and 46.2${\pm}$0.8%, respectively. The temperature measurements in phantom showed that 6$^{\circ}C$ temperature rise was achieved at 2 cm from the applicator surface. As a conclusion, the ability of the ultrasound colpostat applicator to be used for hyperthermia was demonstrated by measuring acoustic output power, ultrasound field distribution, and temperature rise in phantom. Based on the characteristics of this applicator, it has the potential to be useful for inducing hyperthermnia to the vaginal cuff in clinic.

  • PDF

Comparative Evaluation of Two-dimensional Radiography and Three Dimensional Computed Tomography Based Dose-volume Parameters for High-dose-rate Intracavitary Brachytherapy of Cervical Cancer: A Prospective Study

  • Madan, Renu;Pathy, Sushmita;Subramani, Vellaiyan;Sharma, Seema;Mohanti, Bidhu Kalyan;Chander, Subhash;Thulkar, Sanjay;Kumar, Lalit;Dadhwal, Vatsla
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.15 no.11
    • /
    • pp.4717-4721
    • /
    • 2014
  • Background: Dosimetric comparison of two dimensional (2D) radiography and three-dimensional computed tomography (3D-CT) based dose distributions with high-dose-rate (HDR) intracavitry radiotherapy (ICRT) for carcinoma cervix, in terms of target coverage and doses to bladder and rectum. Materials and Methods: Sixty four sessions of HDR ICRT were performed in 22 patients. External beam radiotherapy to pelvis at a dose of 50 Gray in 27 fractions followed by HDR ICRT, 21 Grays to point A in 3 sessions, one week apart was planned. All patients underwent 2D-orthogonal and 3D-CT simulation for each session. Treatment plans were generated using 2D-orthogonal images and dose prescription was made at point A. 3D plans were generated using 3D-CT images after delineating target volume and organs at risk. Comparative evaluation of 2D and 3D treatment planning was made for each session in terms of target coverage (dose received by 90%, 95% and 100% of the target volume: D90, D95 and D100 respectively) and doses to bladder and rectum: ICRU-38 bladder and rectum point dose in 2D planning and dose to 0.1cc, 1cc, 2cc, 5cc, and 10cc of bladder and rectum in 3D planning. Results: Mean doses received by 100% and 90% of the target volume were $4.24{\pm}0.63$ and $4.9{\pm}0.56$ Gy respectively. Doses received by 0.1cc, 1cc and 2cc volume of bladder were $2.88{\pm}0.72$, $2.5{\pm}0.65$ and $2.2{\pm}0.57$ times more than the ICRU bladder reference point. Similarly, doses received by 0.1cc, 1cc and 2cc of rectum were $1.80{\pm}0.5$, $1.48{\pm}0.41$ and $1.35{\pm}0.37$ times higher than ICRU rectal reference point. Conclusions: Dosimetric comparative evaluation of 2D and 3D CT based treatment planning for the same brachytherapy session demonstrates underestimation of OAR doses and overestimation of target coverage in 2D treatment planning.

Development of a cylindrical ultrasound applicator for Intracavitary Hyperthermia (강내온열 치료를 위한 원통형 초음파 치료기 개발)

  • Lee, Rena J.;Hyunsuk Suh
    • Progress in Medical Physics
    • /
    • v.13 no.2
    • /
    • pp.79-84
    • /
    • 2002
  • In this study, a cylindrical ultrasound applicator is developed for the treatment of vagina and rectum in combination with high dose rate brachytherapy. A cylindrical transducer (PZT-8, 1=1.5 cm, thickness=1.5mm OD=2.5 cm) was used as an energy source for induction of hyperthermia. Three single-element applicators were constructed to examine the performance of the PZT material. Vector impedance was measured to determine driving frequency. The efficiencies of the elements were determined using a radiation force technique to evaluate the feasibility of using the applicator as a hyperthermia source. A multi-element ultrasound applicator was designed using the PZT-8 material for the treatment of vagina. Results from the vector impedance measurements showed maximum magnitude at 1.78, 1.77, and 1.77 MHz for applicator 1,2, and 3, respectively. The radiation force measurements showed that the acoustic power of 40 watts was obtained in all three elements. The average efficiencies of the elements were 61.4, 65.2, and 54.0% for element 1, 2, and 3, respectively. The designed ultrasound hyperthermia applicator could be used in combination with high dose rate brachytherapy for the treatment of vagina and rectum. The use of this applicator with intracavitary brachytherapy could offer improved tumor control by increasing radiosensitiyity of the tumor.

  • PDF

Impact of Treatment Time on Chemoradiotherapy in Locally Advanced Cervical Carcinoma

  • Pathy, Sushmita;Kumar, Lalit;Pandey, Ravindra Mohan;Upadhyay, Ashish;Roy, Soumyajit;Dadhwal, Vatsla;Madan, Renu;Chander, Subhash
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.16 no.12
    • /
    • pp.5075-5079
    • /
    • 2015
  • Background: Adverse effects of treatment prolongation beyond 8 weeks with radiotherapy for cervical cancer have been established. Clinical data also show that cisplatin increases the biologically effective dose of radiotherapy. However, there are no data on the effect of overall treatment time in patients with locally advanced cervical cancer treated with concomitant chemo-radiotherapy (CCRT) in an Indian population. The present study concerned the feasibility of concurrent chemotherapy and interspacing brachytherapy during the course of external radiotherapy to reduce the overall treatment time and compare the normal tissue toxicity and loco-regional control with a conventional schedule. Materials and Methods: Between January 2009 and March 2012 fifty patients registered in the Gynaecologic Oncology Clinic of Institute Rotary Cancer Hospital with locally advanced cervical cancer (FIGO stage IIB-IIIB) were enrolled. The patients were randomly allocated to treatment arms based on a computer generated random number. Arm I (n=25) treatment consisted of irradiation of the whole pelvis to a dose of 50 Gy in 27 fractions, and weekly cisplatin $40mg/m^2$. High dose rate intra-cavitary brachytherapy (HDR-ICBT) was performed after one week of completion of external beam radiotherapy (EBRT). The prescribed dose for each session was 7Gy to point A for three insertions at one week intervals. Arm II (n=25) treatment consisted of irradiation of the whole pelvis to a dose of 50 Gy in 27 fractions. Mention HDR-ICBT ICRT was performed after 40Gy and 7Gy was delivered to point A for three insertions (days 23, 30, 37) at one week intervals. Cisplatin $20mg/m^2/day$ was administered from D1-5 and D24-28. Overall treatment time was taken from first day of EBRT to last day of HDR brachytherapy. The overall loco-regional response rate (ORR) was determined at 3 and 6 months. Results: A total of 46 patients completed the planned treatment. The overall treatment times in arm I and arm II were $65{\pm}12$ and $48{\pm}4$ days, respectively (p=0.001). At three and six months of follow-up the ORR for arm I was 96% while that for arm II was 88%. No statistically significant difference was apparent between the two arms. The overall rate of grade ${\geq}3$ toxicity was numerically higher in arm I (n=7) than in arm II (n=4) though statistical significance was not reached. None of the predefined prognostic factors like age, performance status, baseline haemoglobin level, tumour size, lymph node involvement, stage or histopathological subtype showed any impact on outcome. Conclusions: In the setting of concurrent chemoradiotherapy a shorter treatment schedule of 48 days may be feasible by interspacing brachytherapy during external irradiation. The response rates and toxicities were comparable.

CT Based 3-Dimensional Treatment Planning of Intracavitary Brachytherapy for Cancer of the Cervix : Comparison between Dose-Volume Histograms and ICRU Point Doses to the Rectum and Bladder

  • Hashim, Natasha;Jamalludin, Zulaikha;Ung, Ngie Min;Ho, Gwo Fuang;Malik, Rozita Abdul;Ee Phua, Vincent Chee
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.15 no.13
    • /
    • pp.5259-5264
    • /
    • 2014
  • Background: CT based brachytherapy allows 3-dimensional (3D) assessment of organs at risk (OAR) doses with dose volume histograms (DVHs). The purpose of this study was to compare computed tomography (CT) based volumetric calculations and International Commission on Radiation Units and Measurements (ICRU) reference-point estimates of radiation doses to the bladder and rectum in patients with carcinoma of the cervix treated with high-dose-rate (HDR) intracavitary brachytherapy (ICBT). Materials and Methods: Between March 2011 and May 2012, 20 patients were treated with 55 fractions of brachytherapy using tandem and ovoids and underwent post-implant CT scans. The external beam radiotherapy (EBRT) dose was 48.6Gy in 27 fractions. HDR brachytherapy was delivered to a dose of 21 Gy in three fractions. The ICRU bladder and rectum point doses along with 4 additional rectal points were recorded. The maximum dose ($D_{Max}$) to rectum was the highest recorded dose at one of these five points. Using the HDRplus 2.6 brachyhtherapy treatment planning system, the bladder and rectum were retrospectively contoured on the 55 CT datasets. The DVHs for rectum and bladder were calculated and the minimum doses to the highest irradiated 2cc area of rectum and bladder were recorded ($D_{2cc}$) for all individual fractions. The mean $D_{2cc}$ of rectum was compared to the means of ICRU rectal point and rectal $D_{Max}$ using the Student's t-test. The mean $D_{2cc}$ of bladder was compared with the mean ICRU bladder point using the same statistical test. The total dose, combining EBRT and HDR brachytherapy, were biologically normalized to the conventional 2 Gy/fraction using the linear-quadratic model. (${\alpha}/{\beta}$ value of 10 Gy for target, 3 Gy for organs at risk). Results: The total prescribed dose was $77.5Gy{\alpha}/{\beta}10$. The mean dose to the rectum was $4.58{\pm}1.22Gy$ for $D_{2cc}$, $3.76{\pm}0.65Gy$ at $D_{ICRU}$ and $4.75{\pm}1.01Gy$ at $D_{Max}$. The mean rectal $D_{2cc}$ dose differed significantly from the mean dose calculated at the ICRU reference point (p<0.005); the mean difference was 0.82 Gy (0.48-1.19Gy). The mean EQD2 was $68.52{\pm}7.24Gy_{{\alpha}/{\beta}3}$ for $D_{2cc}$, $61.71{\pm}2.77Gy_{{\alpha}/{\beta}3}$ at $D_{ICRU}$ and $69.24{\pm}6.02Gy_{{\alpha}/{\beta}3}$ at $D_{Max}$. The mean ratio of $D_{2cc}$ rectum to $D_{ICRU}$ rectum was 1.25 and the mean ratio of $D_{2cc}$ rectum to $D_{Max}$ rectum was 0.98 for all individual fractions. The mean dose to the bladder was $6.00{\pm}1.90Gy$ for $D_{2cc}$ and $5.10{\pm}2.03Gy$ at $D_{ICRU}$. However, the mean $D_{2cc}$ dose did not differ significantly from the mean dose calculated at the ICRU reference point (p=0.307); the mean difference was 0.90 Gy (0.49-1.25Gy). The mean EQD2 was $81.85{\pm}13.03Gy_{{\alpha}/{\beta}3}$ for $D_{2cc}$ and $74.11{\pm}19.39Gy_{{\alpha}/{\beta}3}$ at $D_{ICRU}$. The mean ratio of $D_{2cc}$ bladder to $D_{ICRU}$ bladder was 1.24. In the majority of applications, the maximum dose point was not the ICRU point. On average, the rectum received 77% and bladder received 92% of the prescribed dose. Conclusions: OARs doses assessed by DVH criteria were higher than ICRU point doses. Our data suggest that the estimated dose to the ICRU bladder point may be a reasonable surrogate for the $D_{2cc}$ and rectal $D_{Max}$ for $D_{2cc}$. However, the dose to the ICRU rectal point does not appear to be a reasonable surrogate for the $D_{2cc}$.

Dose Distribution of Rectum in the treatment of Uterine Cervical Cancer using Remote Afterloading System (RALS시행시 선원의 거리 이동및 직장선량에 관한 계산치와 측정치의 비교연구)

  • 김성규;신세원;김명세
    • Progress in Medical Physics
    • /
    • v.5 no.1
    • /
    • pp.67-74
    • /
    • 1994
  • Dose distribution of point source represents an inverse square law as the distance, Difference of measurement value and calculation value according to moving distance of radiation source show very large error in dose calculation of Brachytherapy. Therefore, in RALS of high dose rate, dose calculation have an important effect in treatment of uterine cervix cancer and recurrent rate. In this paper, authors measured moving distance of radiation source carrying out RALS. And we measured Rectum dose compared with calculationdose.

  • PDF

Real Time On-line Quality Assurance System for HDR Brachytherapy (고선량률 근접 방사선 치료를 위한 실시간 온-라인 정도 관리(QA) 시스템 개발)

  • Lee Su Jin;Lee Re Na;Yi Byang Yang;Lim Sang Waak;Choi Jin Ho
    • Progress in Medical Physics
    • /
    • v.15 no.3
    • /
    • pp.156-160
    • /
    • 2004
  • An essential quality assurance (QA) procedure in high dose rate (HDR) remote after-loading brachytherapy is that of the verification of the Ir-192 HDR source positioning accuracy. A number of methods using mechanical rulers or autoradiograph and video cameras have been reported to check the positional error of the Ir-192 source. In this study, the feasibility of a CMOS (Complementary Metal Oxide Semiconductor) PC camera, with a fluorescent screen, was investigated. The agreement between the planned and measured dwell position was better than 1 mm and dwell times better than 0.4 sec. Our results indicate that the CMOS PC camera system could be used as a QA tool for the on-line determination of the source position and dwell time.

  • PDF